For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.

President-elect Donald Trump has put forward a formal pick for the top spot at the U.S. Food and Drug Administration. | ...

While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the ...

Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of ...

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...

As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the ...

While president-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS ...

With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...

As a council of outside experts prepares to meet Thursday to discuss AstraZeneca’s Andexxa, the FDA has flagged “major safety ...

On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...